Survey on Glucocorticosteriod Associated Osteoporosis in Patients with Rheumatic Diseases in China 2013
张学武,姚海红,梅轶芳,王辉,高娟,林志国,张海宏,王言,赵彦萍,王亮,李洋,李英楠,聂英坤,徐亮,舒强,刘花香,李向培,厉小梅,徐晋,刘璘琛,王艳艳,沈友轩,冷晓梅,吴庆军,王立,赵岩,丁进,李治琴,牛敏,冯媛,陈倩蕴,冷南,王聪华,刘湘源,王芳,王秀娟,张舸,刘宏潇,周惠琼,王丽英,赵千子,李胜光,段婷,周明珠,赵义,黄彦弘,路跃武,黄桂芬,韩峰,戚务芳,张娜,董笑影,孙文闻,高丽霞,王俊祥,陈海英,顾光,李芳,姜国平,刘涛,王晋平,陈雁飞,王晓云,刘斌,李法新,夏丽萍,张榕,赵丽娟,张冶宇,郭韵,薛江霞,刘冬梅,王岩岩,戴冰冰,刘伟,刘畅,华冰珠,丁从珠,顾菲,孙怡宁,莫凌菲,张斌,宁旺斌,潘静,沈凌汛,连莉,黄文辉,林泽英
DOI: https://doi.org/10.3969∕j.issn.1673-8705.2017.03.014
2017-01-01
Abstract:Objective To investigate the incidence and treatment of bone loss in rheumatic patients treated with glucocorticoid in China. Methods From November 1, 2012 to January 31, 2013, 3136 cases of rheumatic disease who had been or were taking glucocorticoid from 46 rheumatology centers nationwide were included and their clinical data, medications, as well as bone mass were investigated. Results (1) RA (1069 cases) and SLE ( 983 cases) patients accounted for the majority . Osteopenia or osteoporosis was observed in 90% of the 3136 patients, and 41. 4% patients were found to be osteoporotic. Nearly half of patients ( 44. 7% ) with a dosage of glucocorticosteroid ( equivalent to prednisone ) >7. 5 mg/d. Even those with a daily dose of glucocorticosteroid (equivalent to prednisone) ≤2. 5 mg, 58. 5% were reported to be osteoporotic. (2) There were increased risk of osteoporosis and fracture with age. In patients younger than 30 years of age, 74. 4% were reported of bone mass reduction or osteoporosis. (3) The incidence of abnormal bone mineral density in women were higher than that in men. The mean age at menopause was lower than that the average (45. 8 years) . (4) Most patients were not giv-en adequate treatment. Prophylactic anti-osteopontin therapy was never given in 32. 7% of patients, nor did 35. 6%of patients with T score <-2. 5 received prophylactic anti-osteoporosis treatment. The mostly used treatment were calcium and vitamin D, 20. 9% received calcium alone, only 4% received bisphosphonates. Conclusion The in-cidence of bone mass reduction or osteoporosis in Chinese rheumatic patients is high while most patients are not giv-en adequate treatment.